Objective: Bovine carotid artery (BCA) grafts have been described as a possibly superior alternative to expanded polytetrafluoroethylene hemoaccess grafts. However, published experience remains limited, and patency rates for nonautogenous arteriovenous grafts remain unsatisfactory. We report herein the largest published experience with the current generation of BCA grafts for dialysis access and analyze subgroups to determine whether obesity, gender, or prior access surgery influences patency.
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend autogenous fistula as the preferred access for hemodialysis patients because of higher patency and lower infection rate compared with prosthetic grafts. 1, 2 However, many patients lack autologous options for arteriovenous (AV) access. Bovine carotid artery (BCA) grafts have shown promise compared with expanded polytetrafluoroethylene (ePTFE) grafts when autologous options are not available, with a markedly superior primary patency rate in one prospective randomized trial. 3 However, the published experience with BCA is limited.
This study aimed to evaluate outcomes in a large series of BCA grafts for hemodialysis.
METHODS
All patients who underwent placement of a BCA graft (Artegraft, New Brunswick, NJ) between 2012 and 2015 were retrospectively reviewed. Revisional procedures were tabulated in a prospectively maintained, retrospectively reviewed database. Demographics, operative reports, complications, patency rates, and additional procedures were analyzed. This study used deidentified patient data; informed consent was waived, and Institutional Review Board approval was waived at both institutions.
All BCA grafts were placed by three board-certified vascular surgeons at a single institution. The KDOQI guidelines were followed with preferential placement of autologous AV fistulas when feasible. Patients had preoperative duplex ultrasound to evaluate the size, depth, and patency of upper extremity veins. AV grafts were used in patients who lacked an upper extremity vein of at least 3 mm in diameter. BCA grafts were placed in a brachial artery to axillary vein configuration and less commonly in an axillary artery to axillary vein "looped" configuration (Fig 1) . Most were performed under general anesthesia. Grafts were tunneled laterally, superficial to the biceps fascia, providing a minimum of 20 cm of accessible length. Anastomoses were performed in an end-to-side fashion. BCA grafts were accessed beginning at 10 days postoperatively. We previously recommended first access attempts at 14 to 21 days for PTFE grafts. Clinical monitoring of grafts was performed by dialysis unit staff. Fistulography was performed on the basis of the KDOQI recommendations, including changes in clinical parameters such as arterial and venous pressures, evidence of recirculation, decreasing Kt/V, and inadequate flow volume. Loss of primary patency was defined as the interval from when the graft was placed until any intervention to maintain or to re-establish patency or graft thrombosis. Loss of primary assisted patency was defined as the interval from graft implantation until first graft. Loss of secondary patency was defined as the interval from construction of the graft until the graft was abandoned.
Data are reported as the mean 6 standard deviation or the range. Kaplan-Meier life-table analysis was performed for primary, primary assisted, and secondary patency. A P value of < .05 was considered significant. All statistical analysis was performed using GraphPad software (GraphPad Software Inc, La Jolla, CA).
RESULTS
Between January 2012 and December 2015, 134 patients had a BCA graft placed as described for hemodialysis access. The average age of the patients was 63.6 years (range, 21-95; standard deviation, 612.5); 54% of patients were male. Patients had an average of 1.8 6 0.7 previous access construction attempts. In the same arm as the current access attempt, patients had an average of 0.4 prior access attempts. A majority of the BCA grafts were placed in a straight configuration (89%; 119 of 134). Only two grafts were placed in the forearm (1.5%). Mean follow-up time was 10 months (range, 1-39 months). There was a 16% mortality rate during follow-up. No mortality was access related.
The primary, primary assisted, and secondary patency rates at 1 year were 32%, 49%, and 78%, respectively (Fig 2) . In the primary assisted patency group of patients, 74% of patients were treated with angioplasty alone, and 26% were treated with angioplasty and stenting; 94% of these procedures were performed for problems with outflow, 3% were performed for inflow problems, and 3% were performed for graft problems. In patients with graft thrombosis, we analyzed the cause of the graft failure; 70% failed secondary to outflow, 7% failed secondary to inflow, 3% failed secondary to graft scarring, and 20% were unknown causes of failure (which includes presumed hypotension). We analyzed several demographics to discern potential differences in patency rates. There was no difference in primary or secondary patency of BCA grafts in men compared with women (P ¼ .88, P ¼ .69; Fig 3) . There was also no difference in primary or secondary patency among patients with body mass index <30 or >30 (primary patency, 28% vs 40% [P ¼ .85]; secondary patency, 80% vs 79% [P ¼ .54]; Fig 4) .
Patients who had a BCA graft placed as their first access attempt had a significantly higher primary and primary assisted patency than patients who had prior access surgery (38% vs 25% at 1 year [P ¼ .039] and 54% vs 41% [P ¼ .024], respectively). However, there was no statistically significant difference in secondary patency rates (P ¼ .49; Fig 5) .
Of the cohort of 134 patients, 10 patients developed a graft infection requiring excision (7%). The mean time from implantation to graft infection was 4.4 months (range, 1-9 months).
The bridge grafts, which are superior alternatives to catheter dialysis. BCA grafts were found to have significantly higher primary patency than the more commonly used ePTFE graft in a randomized trial in which the authors reported 60.5% primary patency at 1 year for BCA compared with 10.1% for ePTFE grafts. 3 HarlanderLocke et al supported these favorable results relative to experience with ePTFE, reporting a 73% primary patency rate at 18 months, but the study included only 17 patients. 4 As yet unpublished work from the Johns Hopkins group suggested a superior secondary patency for BCA compared with ePTFE. 5 Whereas there were reports of a few large series of an earlier version of BCA grafts with favorable results between 1966 and 1986, 6-12 PTFE became the most used graft for bridge fistula by far. This report represents the largest published experience in the modern era.
Based on the promising results of the Massachusetts General Hospital group, 3 we adopted BCA grafts as our primary conduit for dialysis access. In our larger reported experience, we observed a significantly lower primary patency rate of 32%, suggesting a more aggressive posture with regard to prophylactic interventions to maintain patency. Primary patency rates for ePTFE grafts at 1 year reported in the literature generally have ranged from 10% to 40%. 2, 3, 13 Although disappointing, our results
are comparable to what others have reported with ePTFE grafts. Our primary assisted patency rate of 49% was similar to the 60.5% reported in the Massachusetts General Hospital randomized trial, suggesting that more patients are referred for prophylactic interventions from our dialysis units. 3 We hypothesize reasons for our decreased primary patency and increased primary assisted patency compared with this randomized trial. First, there has been substantial growth in outpatient ambulatory access intervention centers in our area, and a proactive posture in patency maintenance has coincided with increased ease of access to these facilities. Second, our patients had a slightly higher number of previous access attempts, 1.8 prior accesses per patient. In addition, only 4% of their patients were obese compared with 29% of our patients. Although we did not find a difference in patency among obese patients, this may signify that our patients had more associated comorbidities than their cohort of patients. For hemoaccess, secondary patency is at least as important as primary patency. Recanalization of an occluded graft allows patients to remain catheter free and preserve sites for future hemoaccess. Our secondary patency at 1 year is 62%, which is slightly better than secondary patency rates of PTFE in the literature (36%-55% at 1 year). 2, 14, 15 Obese patients have been shown to have increased frequency of graft thrombosis in previous studies. 16 Plumb et al demonstrated outflow compression of access secondary to increased axillary fat mass. 17 We have recognized challenges in the growing obese portion of our hemoaccess population and expected higher failure and morbidity rates in this subgroup. However, when we separated our patients into groups of body mass index >30 and <30, we could demonstrate no statistically significant difference between primary patency, primary assisted patency, secondary patency, perioperative morbidity, or long-term infection rate. Likewise, we postulated that women have inferior patency rates compared with men, primarily reflecting smaller vessel size. However, in our series, there was no discernible difference in results based on gender. As might be predicted, patients with prior failed access experience inferior patency results compared with patients having BCA as a first access construction attempt. Unfortunately, after patients have a failed fistula or failed graft, grafts may be the only plausible hemodialysis option, despite this inferior patency. We observed a 7% infection rate in our patients. Hemodialysis access infection in the dialysis population can be devastating. Access infections occur approximately twice as frequently in patients with AV grafts compared with AV fistulas and even more frequently with catheter access. PTFE infection rates in the literature range from 4% to 17%. [18] [19] [20] Whereas numbers are too small for any conclusion of superior resistance to infection to be extrapolated, it is our impression that BCA may carry a lower long-term infection risk than ePTFE. We have noted rapid incorporation and inflammatory response to the grafts, which can be accessed with minimal risk of per-graft extravasation within 10 days. This inflammatory response may translate to lower infection risk, but a larger trial would be needed to examine this. We analyzed the cost of BCA grafts compared with heparin-bonded PTFE. There was a cost saving; however, this may be institution dependent because of discounts. Because of the slightly increased patency of BCA grafts over ePTFE, decreased infection rate, and hypothetical decreased cost per graft, this may confer an advantage in use of BCA grafts over ePTFE.
CONCLUSIONS
This represents the largest published series of BCA grafts used for dialysis access in the modern era. Assisted primary and secondary patency rates are slightly higher than those of ePTFE in the literature, and infection rates appear to be low and acceptable. Larger controlled trials are necessary to define the role of this conduit as the preferred option for prosthetic hemoaccess.
